<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38648015</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2159-3345</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Nucleic acid therapeutics</Title><ISOAbbreviation>Nucleic Acid Ther</ISOAbbreviation></Journal><ArticleTitle>Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2'-<i>O</i>-Methyl Modified Single-Stranded Oligonucleotides.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>155</EndPage><MedlinePgn>143-155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/nat.2023.0056</ELocationID><Abstract><AbstractText>Single-stranded oligonucleotides (SSOs) are a rapidly expanding class of therapeutics that comprises antisense oligonucleotides, microRNAs, and aptamers, with ten clinically approved molecules. Chemical modifications such as the phosphorothioate backbone and the 2'-<i>O</i>-methyl ribose can improve the stability and pharmacokinetic properties of therapeutic SSOs, but they can also lead to toxicity <i>in vitro</i> and <i>in&#xa0;vivo</i> through nonspecific interactions with cellular proteins, gene expression changes, disturbed RNA processing, and changes in nuclear structures and protein distribution. In this study, we screened a mini library of 277 phosphorothioate and 2'-<i>O</i>-methyl-modified SSOs, with or without mRNA complementarity, for cytotoxic properties in two cancer cell lines. Using circular dichroism, nucleic magnetic resonance, and molecular dynamics simulations, we show that phosphorothioate- and 2'-<i>O</i>-methyl-modified SSOs that form stable hairpin structures through Watson-Crick base pairing are more likely to be cytotoxic than those that exist in an extended conformation. In addition, moderate and highly cytotoxic SSOs in our dataset have a higher mean purine composition than pyrimidine. Overall, our study demonstrates a structure-cytotoxicity relationship and indicates that the formation of stable hairpins should be a consideration when designing SSOs toward optimal therapeutic profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Laura V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0003-3875-2753</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbhuiya</LastName><ForeName>Tabassum Khair</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>School of Chemistry and Physics, Centre for Genomics and Personalised Health, Faculty of Science, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Kamand</LastName><ForeName>Serene</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Science, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beard</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajapakse</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamsjaeger</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Science, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubeddu</LastName><ForeName>Liza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Science, Western Sydney University, Penrith, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolderson</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Byrne</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6754-5633</Identifier><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Woolloongabba, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Neha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Centre for Genomics and Personalised Health, Cancer and Ageing Research Program at Translational Research Institute, Faculty of Health, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chemistry and Physics, Centre for Genomics and Personalised Health, Faculty of Science, Queensland University of Technology, Brisbane, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, Manipal Institute of Technology, Manipal Academy of Higher Education, Karnataka, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nucleic Acid Ther</MedlineTA><NlmUniqueID>101562758</NlmUniqueID><ISSNLinking>2159-3337</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054735">Phosphorothioate Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054735" MajorTopicYN="Y">Phosphorothioate Oligonucleotides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009690" MajorTopicYN="Y">Nucleic Acid Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020029" MajorTopicYN="N">Base Pairing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytotoxicity</Keyword><Keyword MajorTopicYN="N">hairpin</Keyword><Keyword MajorTopicYN="N">molecular dynamics simulation</Keyword><Keyword MajorTopicYN="N">oligonucleotide therapeutics</Keyword><Keyword MajorTopicYN="N">phosphorothioate</Keyword><Keyword MajorTopicYN="N">single-stranded oligonucleotides</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>21</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>22</Day><Hour>13</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>22</Day><Hour>11</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38648015</ArticleId><ArticleId IdType="doi">10.1089/nat.2023.0056</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>